The Future of IL-5 in Severe Asthma & Chronic Rhinosinusitis with Nasal Polyps organised by GlaxoSmithkline Pharmaceutical Sdn. Bhd on the 12th of April 2025

Topics :

Rethinking IL-5 and Nucala: A Decade of Optimizing Severe Asthma Management and CRSwNP.
Nucala’s Impact: Real Case Studies on SEA with Comorbid NP, CRSwNP.
Ensuring Cost Effective Care and Access in Severe Asthma Management.
Insights and Answers

Scan the QR to save the date !

Register Now at https://forms.office.com/pages/responsepage.aspx?id=_yqYY2z7IkyXO3DkrPtj5pJJrO-GK0pAsu49doHZrKNUNUVPUVJLVUc0UlU5MlBJNEZDRTQwUjNFUC4u&origin=QRCode&route=shorturl